Career history of Pedro Reiser
Former positions of Pedro Reiser
| Companies | Position | Start | End |
|---|---|---|---|
ESBATech, a Novartis Co. GmbH
 ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Chairman | 2001-12-31 | 2003-12-31 |
Holvis AG
 Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | President | 1989-12-31 | 1994-12-31 |
Training of Pedro Reiser
| University of Zurich | Undergraduate Degree |
| University of Geneva | Doctorate Degree |
Statistics
International
| Switzerland | 5 |
Operational
| Chairman | 1 |
| President | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Consumer Services | 3 |
| Process Industries | 2 |
| Commercial Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Holvis AG
Holvis AG Pulp & PaperProcess Industries Part of Signature Aviation US Topco LLC, Holvis AG is a paper concern. The company is based in Basel, Switzerland. Holvis was acquired by Signature Aviation Ltd., part of Signature Aviation US Topco LLC from June 01, 2021 on June 01, 1995 for $404.89 million. | Process Industries |
ESBATech, a Novartis Co. GmbH
ESBATech, a Novartis Co. GmbH Miscellaneous Commercial ServicesCommercial Services ESBATech AG develops antibody fragment therapeutics. The firm's antibody fragment is derived from human antibody fragment scaffolds. It develops Immuna, an antigen-independent platform to screen, select, and optimize highly-stable and soluble, single-chain antibody fragments. The company was founded by Dominik Escher in September 1998 and is headquartered Schlieren, Switzerland. | Commercial Services |
- Stock Market
- Insiders
- Pedro Reiser
- Experience
